Evaluation of Cirrhosis and Malignant Hepatic Lesions Using Novel MR Contrast Agents
NCT ID: NCT01341132
Last Updated: 2011-04-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
75 participants
OBSERVATIONAL
2011-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gadoxetic Acid-enhanced MR Evaluation of Hepatocellular Carcinoma and Dysplastic Nodules in the Cirrhotic Liver
NCT01501240
Hepatocyte-specific Versus Extracellular Contrast Agents for Liver MRI: Prospective, Intra-individual Comparison of Diagnostic Performance for Hepatocellular Carcinoma
NCT03892681
Added Value of Gadoxetic Acid-enhanced Liver MRI
NCT03045419
Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis
NCT01575574
Identification of Hepatic Lesions
NCT00307866
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Suspected Liver Disease
1. Alpha-feto protein \> 400 ng / mL or
2. prior ultrasound with mass suspicious for hepatic malignancy or.
3. clinical risk of hepatocellular carcinoma or
4. prior multi-detector CT with mass suspicious for possible hepatocellular carcinoma
MRI Scan of the Liver enhanced with Eovist
10mL of gadoxetate disodium administered intravenously while being scanned via the MRI. Images will be attained on a 5, 10 and 20 minute delay. Expected scan time is 45 minutes total
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MRI Scan of the Liver enhanced with Eovist
10mL of gadoxetate disodium administered intravenously while being scanned via the MRI. Images will be attained on a 5, 10 and 20 minute delay. Expected scan time is 45 minutes total
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* prior ultrasound with mass suspicious for hepatic malignancy or.
* clinical risk of hepatocellular carcinoma or
* prior multi-detector CT with mass suspicious for possible hepatocellular carcinoma
Exclusion Criteria
* Previous diagnosis of hepatic malignancy
* Any conditions that would discount the ability to have an MRI scan
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
INDUSTRY
University of California, San Francisco
OTHER
San Francisco Veterans Affairs Medical Center
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
San Francisco Veterans Administration Medical Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rizwan Aslam, MD
Role: PRINCIPAL_INVESTIGATOR
San Francisco VA Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
San Francisco VA Medical Center
San Francisco, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10-03278
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.